Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiomyopathy, Hypertrophic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Cardiomyopathy, Hypertrophic. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-004402-42 Sponsor Protocol Number: HCMRanIT001 Start Date*: 2016-10-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A pilot study assessing the effects of Ranolazine on coronary microvascular dysfunction in patients with hypertrophic cardiomyopathy
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10020204 HOCM Hypertrophic obstructive cardiomyopathy LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020203 HOCM LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10020876 Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004478-32 Sponsor Protocol Number: 03-11-2017 Start Date*: 2018-01-10
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of metoprolol on myocardial function, hemodynamics and heart failure symptoms in patients with hypertrophic obstructive cardiomyopathy
    Medical condition: Hypertrophic obstructive cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10020876 Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001191-19 Sponsor Protocol Number: 2011-400 Start Date*: 2011-10-26
    Sponsor Name:Hjertemedicinsk klinik B, 2142, Rigshospitalet
    Full Title: Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy.
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10020876 Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-001292-14 Sponsor Protocol Number: CV029-009 Start Date*: 2022-11-30
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Le...
    Medical condition: Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-004507-20 Sponsor Protocol Number: MEIN/11/RAN-HCM/001 Start Date*: 2012-01-19
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS
    Medical condition: symptomatic hypertrophic cardiomyopathy (SHCM)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000038-12 Sponsor Protocol Number: 10/0216 Start Date*: 2011-09-13
    Sponsor Name:University College London (UCL)
    Full Title: A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy.
    Medical condition: Hypertrophic cardiomyopathy (non-obstructive)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001577-13 Sponsor Protocol Number: CC-HCM-01 Start Date*: 2014-07-15
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: Copper Chelation in Hypertrophic Cardiomyopathy: Open-label pilot study of Trientine in patients with hypertrophic cardiomyopathy
    Medical condition: Hypertrophic Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003392-10 Sponsor Protocol Number: CMEK162Y2201 Start Date*: 2012-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.
    Medical condition: Noonan syndrome hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    14.1 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-003571-17 Sponsor Protocol Number: CY6022 Start Date*: 2021-08-11
    Sponsor Name:Cytokinetics, Inc.
    Full Title: An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction.
    Medical condition: obstructive hypertrophic cardiomyopathy (oHCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002283-16 Sponsor Protocol Number: 1P50HL112349 Start Date*: 2016-03-08
    Sponsor Name:National Heart, Lung, and Blood Institute / National Institutes of Health
    Full Title: Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric HCM
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10020204 HOCM Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-004429-97 Sponsor Protocol Number: GS-US-361-1157 Start Date*: 2015-03-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy
    Medical condition: Subjects with symptoms (NYHA Class ≥ II dyspnea or CCS Class ≥ II angina) due to hypertrophic cardiomyopathy (defined by standard criteria as a maximal LV wall thickness of ≥ 15 mm in the absence o...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003536-92 Sponsor Protocol Number: CY6031 Start Date*: 2022-05-09
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventric...
    Medical condition: obstructive hypertrophic cardiomyopathy (oHCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) ES (Ongoing) NL (Completed) CZ (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002785-12 Sponsor Protocol Number: CY6021 Start Date*: 2020-05-25
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A multi-center, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CK-3773274 in adults with symptomati...
    Medical condition: obstructive hypertrophic cardiomyopathy (oHCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004317-24 Sponsor Protocol Number: MN2015-1/A Start Date*: 2017-06-22
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: “A pilot study to assess Coronary Flow Reserve and post-vasodilatatory Myocardial Blood Flow (post-Dipi gMBF), measured by 13N-NH3 PET/CT, before and after a six months-long treatment with the AC...
    Medical condition: Hypertrophic Cardiomyopathy (primitive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005329-26 Sponsor Protocol Number: CV027-031 Start Date*: 2023-01-24
    Sponsor Name:Myokardia, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
    Medical condition: Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10049813 Non-obstructive cardiomyopathy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) IT (Prematurely Ended) NL (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003958-86 Sponsor Protocol Number: GS-US-356-5413 Start Date*: 2022-06-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Study of Females Exposed to Eleclazine
    Medical condition: The goal of this study is to follow up with female subjects who received eleclazine in prior clinical trials for ischemic heart disease, ventricular arrhythmia, hypertrophic cardiomyopathy or long ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10055218 Ischemic heart disease LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.1 10007541 - Cardiac disorders 10024803 Long QT syndrome PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) IT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003098-24 Sponsor Protocol Number: CLCZ696I12201 Start Date*: 2019-12-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, randomized, placebo-controlled patient and investigator-blinded study to explore the efficacy of oral sacubitril/valsartan in adult patients with non-obstructive hypertrophic cardio...
    Medical condition: non-obstructive hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002530-23 Sponsor Protocol Number: MYK-461-005 Start Date*: 2018-10-04
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
    Medical condition: Hypertrophic Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) PL (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002242-17 Sponsor Protocol Number: B00844 Start Date*: 2020-07-30
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: A randomised, double-blind, placebo-controlled, phase 2 evaluation of the efficacy and mechanism of trientine in patients with hypertrophic cardiomyopathy.
    Medical condition: Hypertrophic Cardiomyopathy (HCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-001660-38 Sponsor Protocol Number: FLORAMICAR2 Start Date*: 2018-01-18
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: A prospective triple-arm, monocentric, phase-II explorative study on evaluation of diagnostic efficacy of the PET tracer (18F)-florbetaben (Neuraceq®) in patients with cardiac amyloidosis - FLORAMI...
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:20:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA